skip to Main Content

Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

Long-Term Administration Of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline In Mice

Kathryn F. Mills, Shohei Yoshida,
Liana R. Stein, …, Koji Uchida,
Jun Yoshino, Shin-ichiro Imai

Correspondence (J.Y.), (S.I.)

Mills et al. conducted a 12-month-long administration of nicotinamide mononucleotide (NMN), a key natural NAD+ intermediate, to normal wild-type mice, demonstrating that NMN effectively mitigates age-associated physiological decline in mice without any obvious toxicity. These results highlight the significant potential of NMN as an effective anti-aging intervention in humans.

About Us

EZZ Life Science Holdings Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health.  EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management.  EZZ is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide.

Come Say Hi

EZZ Australia & New Zealand © All Rights Reserved